The isoprostanes - Unique products of arachidonate peroxidation: Their role as mediators of oxidant stress

被引:112
作者
Morrow, JD
机构
[1] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA
关键词
isoprostane; peroxidation; free radical; eicosanoid; thromboxane receptor;
D O I
10.2174/138161206776055985
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The isoprostanes (IsoPs) are a series of novel prostaglandin-like compounds formed in vivo in humans from the free radical-catalyzed peroxidation of arachidonate independent of the cyclooxygenase. While quantification of these compounds is a highly accurate measure of oxidant stress in vivo in humans. IsoPs also possess potent biological activity and likely mediate certain aspects of oxidative injury. The purpose of this review is to summarize selected aspects of our knowledge regarding the bioactivity of the IsoPs. I will first briefly highlight mechanisms involved in IsoP formation. Subsequently, I will discuss the biological activities of certain IsoPs that are formed in abundance in vivo and focus on two compounds, 15-F-2t-IsoP and 15-E-2t-IsoP, that have been Studied in the greatest detail. This review will then examine, at a molecular level, mechanisms by which IsoPs exert their bioactivity. It has been shown that they are ligands for various eicosanoid receptors, in particular, the thromboxane receptor. In addition, I will discuss the controversial evidence that a unique IsoP receptor(s) exists. Finally, I will offer avenues for future research related to the development of pharmacological approaches to modulate IsoP formation and action in vivo and thus decrease the pathophysiological sequelae of oxidative injury.
引用
收藏
页码:895 / 902
页数:8
相关论文
共 47 条
[1]   DIETARY CARCINOGENS AND ANTICARCINOGENS - OXYGEN RADICALS AND DEGENERATIVE DISEASES [J].
AMES, BN .
SCIENCE, 1983, 221 (4617) :1256-1264
[2]   Cardiovascular responses to the isoprostanes iPF2α-III and iPE2-III are mediated via the thromboxane A2 receptor in vivo [J].
Audoly, LP ;
Rocca, B ;
Fabre, JE ;
Koller, BH ;
Thomas, D ;
Loeb, AL ;
Coffman, TM ;
FitzGerald, GA .
CIRCULATION, 2000, 101 (24) :2833-2840
[3]   Isoprostanes and the kidney [J].
Badr, KF ;
Abi-Antoun, TE .
ANTIOXIDANTS & REDOX SIGNALING, 2005, 7 (1-2) :236-243
[4]   EFFECTS OF A NOVEL PROSTAGLANDIN, 8-EPI-PGF2-ALPHA, IN RABBIT LUNG INSITU [J].
BANERJEE, M ;
KANG, KH ;
MORROW, JD ;
ROBERTS, LJ ;
NEWMAN, JH .
AMERICAN JOURNAL OF PHYSIOLOGY, 1992, 263 (03) :H660-H663
[5]  
Cyrus T, 2001, CIRCULATION, V103, P2277
[6]   Oxidative stress during myocardial ischaemia and heart failure [J].
Ferrari, R ;
Guardigli, G ;
Mele, D ;
Percoco, GF ;
Ceconi, C ;
Curello, S .
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (14) :1699-1711
[7]  
FUKUNAGA M, 1995, J CARDIOVASC PHARM, V26, pS51
[8]   Evidence for the distinct nature of F-2-isoprostane receptors from those of thromboxane A(2) [J].
Fukunaga, M ;
Yura, T ;
Grygorczyk, R ;
Badr, KF .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 1997, 272 (04) :F477-F483
[9]   EVIDENCE FOR THE EXISTENCE OF F2-ISOPROSTANE RECEPTORS ON RAT VASCULAR SMOOTH-MUSCLE CELLS [J].
FUKUNAGA, M ;
MAKITA, N ;
ROBERTS, LJ ;
MORROW, JD ;
TAKAHASHI, K ;
BADR, KF .
AMERICAN JOURNAL OF PHYSIOLOGY, 1993, 264 (06) :C1619-C1624
[10]  
HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1